BofA upgraded Danaher (DHR) to Buy from Neutral with an unchanged price target of $290. The recent pullback has created a more attractive entry point, says the firm, which believes shares may outperform in 2025 as bioprocess recovery takes center stage amid “more realistic” buyside expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher upgraded to Buy from Neutral at BofA
- Danaher put volume heavy and directionally bearish
- Third Point exits Alphabet, cuts stakes in Microsoft, Amazon, Meta, Apple
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
- Danaher upgraded to Outperform from Peer Perform at Wolfe Research